Home
About Us
Membership
Member Biography

Member Biography

Greg Durm, MD

Greg Durm, M.D.

Phone: (317) 278-0067
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
RT 445
Indianapolis, IN 46202

Faculty appointments

Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Associate Professor of Clinical Otolaryngology-Head & Neck Surgery, Department of Otolaryngology -- Head and Neck Surgery, IU School of Medicine
Full member, Experimental and Developmental Therapeutics

My current interests are in the development of novel approaches to the treatment of lung cancer, in particular, immunotherapy-based approaches. I have two ongoing trials looking at consolidation immunotherapy following standard of care chemoradiation for stage III NSCLC. I also have trials looking at the utility of continuing immunotherapy after progression in metastatic NSCLC and the addition of immunotherapy to chemoradiation and surgery in operable stage III NSCLC. Our studies include many correlatives to help define key biomarkers for response and toxicity during treatment with immune therapy agents, and we are looking at ways to improve the early detection of cancer cells in patients who have undergone curative therapy. I have collaborations with labs both at Indiana University and other cancer centers working to improve translational research and bring new therapies and tests from the bench to the bedside. I have also worked to implement a portfolio of clinical trials for patients with cancers of the head and neck.

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100).20170543

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to CisplatinNRG-HN004

A Randomized Phase II/III Trials of De-Intensified Radiation Therapy For patients with Early Stage, P-16, Positive, Non-Smoking Associated Oropharyngeal Cancer.RAON-NRG-HN005

A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153 CTO-BTCRC-LUN18-153

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.RAON-NRG-LU005

A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics,pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumorsCTO-20210023

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer Big Ten Cancer Research Consortium BTCRC- LUN20-462CTO-BTCRC-LUN20-462

Biomarkers of DNA Damage Repair and Response to Platinum-Based Chemotherapy and/or Radiation in Lung, Esophageal, and Head/Neck CancersCTO-IUSCCC-0796

Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW2992)in Combination with Capecitabine for Advanced Solid Tumors and Pancretico- Biliary CancersCC9078

Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)RAON-ECOG-ACRIN-EA3132

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C MutationCTO-20190135

NO TITLE1381-0009

Evaluation of MRM-Profiling as a Small Molecule Biomarker-Enrichment Strategy in Oncological Clinical TrialsIUSCC-0709

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid TumorsCTO-LOXO-RAS-20001

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer CTO-HCRN-LUN21-497

A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid TumorsCTO-M19-345

Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)CTO-J2272

A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinomaCTO-MCLA-158-CL02

A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell CarcinomaCTO-LCCC2047

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 ExpressionCTO-J3M-MC-JZQB

A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid TumorsCTO-J5Q-OX-JRDA

A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients with Locally Advanced or Metastatic Solid TumorsCTO-DAY301-001

Headlines & highlights

Junior IU oncologist selected to present oral abstract at world’s leading oncology group (June 2018)

#ResearchCuresCancer

Support Our Research